Skip to content

NARCOMS Registry: A Multiple Sclerosis Registry

NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01018537
Acronym
NARCOMS
Enrollment
50000
Registered
2009-11-23
Start date
1996-01-31
Completion date
2050-12-31
Last updated
2025-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, NARCOMS, Patient Registry, Registry

Brief summary

This project is based on the idea that we can learn about the complexities of MS by following disease and treatment patterns in a large group of people over several years. The information gathered is used for research only. Results are presented in summary form only. All details submitted by registry participants is strictly confidential. To participate in NARCOMS complete the baseline enrollment survey online through www.narcoms.org (or directly using the following link: https://redcap.link/py2rnyyn) or you can request a mail-in survey be sent to you by emailing MSregistry@narcoms.org. You will be asked to update your information, online or by mail, twice a year. Each update survey typically takes less than 20 minutes to complete. There is no cost to participate. For your participation you are offered a free subscription to the NARCOMS quarterly magazine, NARCOMS Now. NARCOMS Now provides a reliable source of information about the latest in MS research and disease management. You can stop participating in the registry at any time. You may also receive additional surveys or information on clinical trials. You are not obligated to participate and these additional studies will always come directly from NARCOMS. Your contact information will not be shared or sold to other parties.

Detailed description

The data coordinating center, located at the University of Texas Southwestern Medical Center, maintains NARCOMS, the worlds largest voluntary, patient driven MS registry. The registry involves personnel from at least three other sites in the US and Canada (Cleveland Clinic Foundation, University of Alabama at Birmingham, and the Dalhousie University in Canada). Over the past 30 years more than 42,000 people with MS across the U.S., Canada and over 50 other countries, including over 4,000 Veterans, have participated in the registry by submitting their health-related data by mail or online. Registry data have been featured in over 100 peer-reviewed journal articles, scientific posters and presentations. These reports have provided information to guide new research. They also provide evidence supporting the approval of new drugs in the fight against MS. The North American Research Committee on Multiple Sclerosis (NARCOMS) is supported in part by the Consortium of Multiple Sclerosis Centers (CMSC), a not-for-profit professional organization for multiple sclerosis (MS) healthcare providers and researchers involving 198 participating centers of the MS treatment and research community.

Interventions

None listed

Sponsors

Consortium of Multiple Sclerosis Centers
CollaboratorOTHER
University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any individual who has been diagnosed with multiple sclerosis or clinically isolated syndrome * Must be at least 18 years of age

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Disease progression over time of follow upup to 15 yearsDisease Progression measured using the Patient Determined Disease Steps

Secondary

MeasureTime frameDescription
Contributing factors to change in MS disease statusup to 15 yearsFactors include, but not limited to, demographics, lifestyle and clinical characteristics

Other

MeasureTime frameDescription
Medication usage in multiple sclerosisup to 15 yearsDisease modifying therapy use is collected from participants

Countries

United States

Contacts

Primary ContactNARCOMS Team
MSregistry@narcoms.org1-214-648-4583

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026